GENinCode plc
GENI
Rank in Stocks
#30389
GENinCode Plc specializes in the creation and commercialization of advanced... GENinCode Plc specializes in the creation and commercialization of advanced genetic tests designed to forecast potential health risks based on an individual's DNA. Operating in both the United Kingdom and internationally, their predictive technology empowers individuals and medical professionals alike with proactive health management and targeted intervention strategies. The company's sophisticated molecular diagnostics leverage a combination of clinical algorithms and artificial intelligence to deliver precise patient risk assessments, thereby anticipating the onset of various diseases. Among their specialized tests are: Cardio inCode: A patented genetic assay designed to guide individuals in cardiovascular prevention. Lipid inCode: A genetic diagnostic tool that analyzes seven specific genes associated with familial hypercholesterolemia. SUDD inCode: A genetic test to identify the underlying causes of sudden cardiac death and inherited heart conditions. Thrombo inCode: This test assesses 12 genetic variants linked to hereditary thrombophilia and the general risk of thrombosis (blood clots). Thrombo inCode Reproductive Health: Offering crucial insights into thrombophilia risks particularly relevant to prospective pregnancies. Established in 2018, GENinCode Plc maintains its headquarters in Oxford, United Kingdom.
Share Price
$0.00769889
Last synced: 2026-11-12
Market Cap
$5.13M
Change (1 day)
-3.86%
Change (1 year)
-74.56%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade GENinCode plc (GENI)
Category
Healthcare
Operating Margin for GENinCode plc (GENI)
Operating Margin as of November 2026 TTM: -228.32%
According to GENinCode plc's latest financial reports, its current operating margin (TTM) is -228.32%. At the end of 2025 the company had an operating margin of -191.58%.
Operating Margin history for GENinCode plc from 2019 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -228.32% | 19.18% |
| 2025 | -191.58% | 0.79% |
| 2024 | -190.08% | -42.58% |
| 2023 | -331.06% | -19.75% |
| 2022 | -412.52% | 34.70% |
| 2021 | -306.24% | 180.23% |
| 2020 | -109.28% | 322.26% |
| 2019 | -25.88% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 17.98% | -100.08% |
US
|
|
| 20.38% | -100.09% |
US
|
|
| 43.02% | -100.19% |
CN
|
|
| 32.30% | -100.14% |
US
|
|
| 22.23% | -100.10% |
US
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about GENinCode plc's operating margin
What is GENinCode plc's operating margin?
GENinCode plc's operating margin is -228.32%, as of Nov 2026.
What was GENinCode plc's operating margin in 2025?
In 2025, GENinCode plc's operating margin was -191.58%, compared with -190.08% in 2024.
How has GENinCode plc's operating margin changed since 2020?
From 2020 to 2025, GENinCode plc's operating margin was highest in 2020 (-109.28%) and lowest in 2022 (-412.52%).
How does GENinCode plc's operating margin compare with similar companies?
GENinCode plc's operating margin (-228.32%) is lower than that of all 5 similar companies listed above. The highest among them is WuXi AppTec Co., Ltd., with 43.02%.